N-[2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-6-yloxy)ethyl]-3-(3,4-difluorophenyl)propionamide | 1008798-43-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: N-[2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-6-yloxy)ethyl]-3-(3,4-difluorophenyl)propionamide
• 英文别名: N-[2-[3-[4-[[benzyl(ethyl)amino]methyl]phenyl]-2-oxochromen-6-yl]oxyethyl]-3-(3,4-difluorophenyl)propanamide
• CAS: 1008798-43-3
• 化学式: C₃₆H₃₄F₂N₂O₄
• 分子量: 596.674
• InChiKey: VXLNOYAINXJRCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  44
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-(2-aminoethoxy)-3-{4-[(benzylethylamino)methyl]phenyl}-chromen-2-one 、 3-(3,4-二氟苯基)丙酸 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-[2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-6-yloxy)ethyl]-3-(3,4-difluorophenyl)propionamide
  参考文献：
  名称：

  Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

  摘要：

  The complex etiology of Alzheimer's disease (AD) prompts scientists to develop multifunctional compounds to combat causes and symptoms of such neurodegeneration. To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor. The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD. (c) 2007 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2007.09.100

文献信息

• Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds
  作者：Lorna Piazzi、Andrea Cavalli、Francesco Colizzi、Federica Belluti、Manuela Bartolini、Francesca Mancini、Maurizio Recanatini、Vincenza Andrisano、Angela Rampa

  DOI：10.1016/j.bmcl.2007.09.100

  日期：2008.1

  The complex etiology of Alzheimer's disease (AD) prompts scientists to develop multifunctional compounds to combat causes and symptoms of such neurodegeneration. To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor. The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD. (c) 2007 Published by Elsevier Ltd.